PMID- 30572252
OWN - NLM
STAT- MEDLINE
DCOM- 20190509
LR  - 20190509
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 67
DP  - 2019 Feb
TI  - Regulatory B cells in inflammatory diseases and tumor.
PG  - 281-286
LID - S1567-5769(18)30458-2 [pii]
LID - 10.1016/j.intimp.2018.12.007 [doi]
AB  - As antigen-presenting cells (APC), B cells exert a variety of immune regulatory 
      functions mainly by presenting antigens, triggering immune response, and 
      producing antibodies for immune regulation. Regulatory B cells (Bregs) are 
      special subpopulations of B cells with immune-regulating or immune-suppressing 
      properties and play a role in peripheral tolerance. Bregs suppress immune 
      response through inhibiting the differentiation of dendritic cells (DCs), 
      suppressing the proliferation of helper T1(TH1) cells and helper T17 (TH17) 
      cells, inducing the differentiation of fork head transcription factor p3 positive 
      regulatory T cells (FoxP3(+) Tregs). Different subsets of Bregs have distinct 
      phenotypes and markers. Different subsets of Bregs participate in immune 
      modulation by different ways. The absence or loss of Bregs exacerbates the 
      severity of many disease such as rheumatoid arthritis (RA), systemic lupus 
      erythematosus (SLE) and graft-versus-host-disease (GVHD). Bregs are also involved 
      in tumor immunosuppressive effect and inhibit the antitumor immune process. In 
      this article, we review the research advances of Bregs in autoimmune diseases, 
      GVHD and tumor.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Cai, Xiaoyu
AU  - Cai X
AD  - Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of 
      Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative 
      Innovation, China; Center of Anti-inflammatory and Immune Medicine, Hefei 230032, 
      Anhui Province, China.
FAU - Zhang, Lingling
AU  - Zhang L
AD  - Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of 
      Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative 
      Innovation, China; Center of Anti-inflammatory and Immune Medicine, Hefei 230032, 
      Anhui Province, China. Electronic address: llzhang@ahmu.edu.cn.
FAU - Wei, Wei
AU  - Wei W
AD  - Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of 
      Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative 
      Innovation, China; Center of Anti-inflammatory and Immune Medicine, Hefei 230032, 
      Anhui Province, China. Electronic address: wwei@ahmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181217
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
SB  - IM
MH  - Animals
MH  - B-Lymphocytes, Regulatory/*physiology
MH  - Humans
MH  - Inflammation/*metabolism
MH  - Neoplasms/*metabolism
OTO - NOTNLM
OT  - Autoimmune diseases
OT  - Bregs
OT  - GVHD
OT  - Graft-versus-host-disease
OT  - Regulatory B cells
OT  - Tumor
EDAT- 2018/12/21 06:00
MHDA- 2019/05/10 06:00
CRDT- 2018/12/21 06:00
PHST- 2018/08/22 00:00 [received]
PHST- 2018/11/12 00:00 [revised]
PHST- 2018/12/03 00:00 [accepted]
PHST- 2018/12/21 06:00 [pubmed]
PHST- 2019/05/10 06:00 [medline]
PHST- 2018/12/21 06:00 [entrez]
AID - S1567-5769(18)30458-2 [pii]
AID - 10.1016/j.intimp.2018.12.007 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Feb;67:281-286. doi: 10.1016/j.intimp.2018.12.007. Epub 
      2018 Dec 17.